Moderna (NASDAQ:MRNA) PT Lowered to $139.00

Moderna (NASDAQ:MRNA) had its target price reduced by equities researchers at The Goldman Sachs Group from $178.00 to $139.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target indicates a potential upside of 93.08% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group cut Moderna from a “buy” rating to a “hold” rating and decreased their price target for the stock from $120.00 to $65.00 in a report on Friday, September 13th. JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and decreased their target price for the company from $88.00 to $70.00 in a research note on Friday, September 13th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Finally, Royal Bank of Canada dropped their target price on Moderna from $90.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $100.44.

Moderna Stock Performance

NASDAQ:MRNA opened at $71.99 on Monday. The firm’s fifty day simple moving average is $93.23 and its 200 day simple moving average is $111.56. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna has a twelve month low of $62.55 and a twelve month high of $170.47. The firm has a market capitalization of $27.59 billion, a price-to-earnings ratio of -4.59 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the previous year, the firm posted ($3.62) earnings per share. The firm’s quarterly revenue was down 29.9% on a year-over-year basis. As a group, equities research analysts expect that Moderna will post -9.52 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total transaction of $1,756,200.00. Following the sale, the director now owns 2,269,015 shares in the company, valued at approximately $265,656,276.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC bought a new stake in Moderna in the 2nd quarter valued at about $26,000. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna in the fourth quarter valued at approximately $27,000. Cedar Wealth Management LLC raised its holdings in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new position in shares of Moderna during the first quarter worth approximately $32,000. Finally, Family Firm Inc. bought a new position in Moderna in the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.